The Johnson & Johnson vaccine against COVID-19 is significantly less effective against variants, compared to the two other COVID-19 vaccines authorized for use in the United States, a pre-print study by scientists from the New York University School of Medicine suggests.
According to the paper’s summary, the antibodies elicited by the two-dose Pfizer–BioNTech and Moderna vaccines “showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants.” In contrast, the antibodies generated in response to the single-dose Johnson & Johnson vaccine had “significantly decreased neutralization.”
